The use and discontinuation of hormone replacement therapy in women in South China

被引:29
作者
Chu, K. [1 ]
Song, Y. [1 ]
Chatooah, N. D. [1 ]
Weng, Q. [2 ]
Ying, Q. [3 ]
Ma, L. [1 ]
Qu, F. [1 ]
Zhou, J. [1 ]
机构
[1] Zhejiang Univ, Womens Hosp, Sch Med, 1st Xueshi Rd, Hangzhou 310006, Zhejiang, Peoples R China
[2] Yuhang First Hosp, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
关键词
Hormone replacement therapy; discontinuation; China; menopause; RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; MENOPAUSAL SYMPTOMS; HEALTH; PREVENTION; KNOWLEDGE; DISEASE;
D O I
10.1080/13697137.2017.1397622
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The use of hormone replacement therapy (HRT) started later in China than in European countries. The purpose of the present study was to investigate HRT patterns and reasons for the initiation and discontinuation of HRT among women in South China. Methods: A telephone survey about menopausal status, the use of HRT, reasons for HRT discontinuation and duration of HRT treatment was conducted in 2014. Results: A total of 825 telephone surveys were carried out, and 217 previous HRT users and 390 current users were recruited for this study. Among these 607 subjects, 50.7% of the women sought out HRT for hot flushes, 41.6% for fatigue and 41.5% for sleeplessness. Approximately one-third (35.9%) of the patients abandoned HRT during the following year. The reasons for stopping HRT were mainly fear of breast and uterine cancer (28.4%), reduced menopausal symptoms (22.9%) and the inconvenience of taking pills or seeing a doctor (17.9%). The factors related to HRT discontinuation were the age when HRT was initiated (odds ratio 1.59, 95% confidence interval 1.19-2.13) and education level (odds ratio 0.78, 95% confidence interval 0.62-0.98). Conclusions: The duration of HRT use in women in south China was short, and a high proportion of the women discontinued HRT. Given the high discontinuation rate and the low medical compliance, Chinese health-care providers still have much to do to let women know about the advantages and disadvantages of HRT and to encourage the use of HRT appropriately.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 31 条
[1]   2016 IMS Recommendations on women's midlife health and menopause hormone therapy [J].
Baber, R. J. ;
Panay, N. ;
Fenton, A. .
CLIMACTERIC, 2016, 19 (02) :109-150
[2]   The impact of the women's health, initiative on discontinuation of postmenopausal hormone therapy: The Minnesota Heart Survey (2000-2002) [J].
Barber, CA ;
Margolis, K ;
Luepker, RV ;
Arnett, DK .
JOURNAL OF WOMENS HEALTH, 2004, 13 (09) :975-985
[3]   Transdermal estrogens in the changing landscape of hormone replacement therapy [J].
Beck, Keli L. ;
Anderson, Michelle C. ;
Kirk, Julienne K. .
POSTGRADUATE MEDICINE, 2017, 129 (06) :632-636
[4]   A multicentric study regarding the use of hormone therapy during female mid-age (REDLINC VI) [J].
Bluemel, J. E. ;
Chedraui, P. ;
Baron, G. ;
Benitez, Z. ;
Flores, D. ;
Espinoza, M. T. ;
Gomez, G. ;
Gonzalez, E. ;
Hernandez, L. ;
Lima, S. ;
Martino, M. ;
Montano, A. ;
Monterrosa, A. ;
Mostajo, D. ;
Ojeda, E. ;
Onatra, W. ;
Robles, C. ;
Saavedra, J. ;
Sanchez, H. ;
Tserotas, K. ;
Vallejo, M. S. ;
Vallejo, C. .
CLIMACTERIC, 2014, 17 (04) :433-441
[5]  
Cen X, 1993, J REPROD MED, V1, P23
[6]  
Chundong L, 2015, CHONGQING MED, V28, P3978
[7]   AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE [J].
Cobin, Rhoda H. ;
Goodman, Neil F. .
ENDOCRINE PRACTICE, 2017, 23 (07) :869-880
[8]   Compliance with hormone replacement therapy in postmenopausal Sicilian women [J].
Corrado, F ;
D'Anna, R ;
Caputo, F ;
Cannata, ML ;
Zoccali, MG ;
Cancellieri, F .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2005, 118 (02) :225-228
[9]  
Harlow SD, 2012, CLIMACTERIC, V15, P105, DOI [10.1097/gme.0b013e31824d8f40, 10.3109/13697137.2011.650656, 10.1016/j.fertnstert.2012.01.128, 10.1210/jc.2011-3362]
[10]  
Hongxue L, 2012, PROGR MODERN BIOMED, V21, P4065